Axcella Announces Upcoming Presentations at NASH-TAG 2021
February 25 2021 - 7:55AM
Business Wire
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company
pioneering a new approach to treat complex diseases and improve
health using endogenous metabolic modulator (EMM) compositions,
today announced three upcoming presentations at the NASH-TAG 2021
Conference, which is taking place March 11-13. Among the
information to be shared by Axcella at this event will be clinical
data regarding AXA1125, the company’s multi-targeted product
candidate for nonalcoholic steatohepatitis (NASH) that is entering
Phase 2b clinical development. Additionally, new in-depth insights
into the mechanism of action for AXA1125 will be provided. The
presentation details are as follows:
- Abstract #22: “Mechanistic insights into AXA1125,
a novel endogenous metabolic modulator composition, targeting
multiple NASH drivers”
- Abstract #33: Distinguished Abstract and Poster
Award to be presented by Nadege T. Gunn, M.D., Lead Physician
Investigator at Pinnacle Clinical Research in Austin, TX and
Adjunct Assistant Professor at Texas A&M University College of
Medicine. “Safety, tolerability, and biological activity of AXA1125
and AXA1957 in a prospective 16-week randomized, placebo-controlled
study in subjects with NAFLD with and without type 2 diabetes”
- Abstract #34: “Biological activity of AXA1125 and
AXA1957 on glucose, insulin, HOMA-IR, and HbA1c and measures of
liver fat and fibroinflammation in a prospective 16-week
randomized, placebo-controlled study in subjects with NAFLD and
type 2 diabetes”
NASH-TAG brings together clinicians and researchers from
academia and the biopharmaceutical industry for interactive
educational presentations highlighting the most relevant advances
and challenges in the diagnosis and therapy of NASH and liver
fibrosis. Internationally renowned faculty assist in the
development of the educational content and serve as faculty at the
conference. Given the hybrid nature of the conference in 2021, all
presentations will be in poster format.
About Endogenous Metabolic Modulators (EMMs)
EMMs are a broad family of molecules, including amino acids,
that regulate human metabolism. Axcella is developing a range of
novel product candidates that are comprised of multiple EMMs
engineered in distinct combinations and ratios to simultaneously
impact multiple metabolic pathways to modify the root causes of
various complex diseases and improve health.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation FD. Such disclosures
will be included on the company’s website in the “Investors and
News” section. Accordingly, investors should monitor this portion
of the company’s website, in addition to following its press
releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a
new approach to treat complex diseases and improve health using
endogenous metabolic modulator (EMM) compositions. The company’s
product candidates are comprised of EMMs and their derivatives that
are engineered in distinct combinations and ratios to
simultaneously impact multiple biological pathways. Axcella’s
pipeline includes lead therapeutic candidates for non-alcoholic
steatohepatitis (NASH) and the reduction in risk of overt hepatic
encephalopathy (OHE) recurrence. For more information, please visit
www.axcellahealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210225005043/en/
Jason Fredette jfredette@axcellahealth.com 857.320.2236
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to Apr 2024